News
VINCU
27.00
0.00%
0.00
VINCERX PHARMA INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 16 MLN SHARES OF ITS COMMON STOCK AT A COMBINED PRICE OF $0.75 PER SHR
Reuters · 17h ago
VINCERX PHARMA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Chemours, Lucid, OppFi
U.S. Stocks reverse early gains ahead of key inflation print. Dow Jones Industrial Average down 0.36%; S&P 500 and Nasdaq Composite also down. Chemours, Lucid, OppFi among the top stocks on the move. Lucid Group down 3.9% after announcing potential sale of parts of company.
Reuters · 04/09 18:19
BUZZ-U.S. STOCKS ON THE MOVE-Digital Realty, Alphabet, Moderna
Dow Jones Industrial Average was down 0.52% on Tuesday. Wall Street's main stock indexes gained on Tuesday supported by retreating Treasury yields. Investors await a key inflation print later in the week that could help shape the Fed's stance on interest-rate cuts. Digital Realty, Alphabet, Moderna are among the day's top stocks.
Reuters · 04/09 16:20
BUZZ-U.S. STOCKS ON THE MOVE-Bloom Energy, Hecla Mining, Alkermes
U.S. Stocks were poised for a higher open on Tuesday. Dow e-minis were up 0.05% ahead of a key inflation print later in the week. Top three NYSE percentage gainers premarket were Leju Holdings, Hecla Mining. Bloom Energy, American Eagle Outfitters, Alkermes among stocks on the move.
Reuters · 04/09 13:23
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Taysha Gene, American Eagle
U.S. Stock index futures were flat on Tuesday ahead of a crucial inflation reading later in the week. Gold miners, Taysha Gene, American Eagle and Bloom Energy are among the top stocks on the move. Dow e-minis were down 0.02% ahead of the open.
Reuters · 04/09 11:54
VINCERX PHARMA SHARES DOWN 53.1% PREMARKET AFTER CANCER THERAPY STUDY DATA COMES IN BELOW EXPECTATIONS
Reuters · 04/09 10:53
BUZZ-Vincerx Pharma tumbles as cancer therapy study data comes in below expectations
Shares of Vincerx Pharma slump 51.5% to $2.32 premarket after cancer therapy study data comes in below expectations. Company's experimental cancer therapy VIP236 demonstrated some anti-tumor activity, but was below investor expectations. Stock up three-fold YTD.
Reuters · 04/09 10:03
VINCERX PHARMA PRESENTS POSITIVE PRELIMINARY PHASE 1 DATA FOR VIP236 AND UPDATES ON PIPELINE PROGRESS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2024
Reuters · 04/08 20:30
Vincerx Pharma Inc reports results for the quarter ended in December - Earnings Summary
Vincerx Pharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 23 cents per share. The mean expectation of three analysts was for a loss of 37 cents. Reported revenue was zero; analysts expected zero. Shares had risen by 413.6% this quarter.
Reuters · 03/29 21:03
Vincerx Pharma Inc <VINC.OQ> expected to post a loss of 37 cents a share - Earnings Preview
Vincerx Pharma Inc expected to post a loss of 37 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 26. Average analyst rating on the shares is "buy" and the median 12-month price target is $9.00.
Reuters · 03/22 11:03
BUZZ-U.S. STOCKS ON THE MOVE-US energy sector, Avis, NuScale
The tech-laden Nasdaq dipped on Tuesday with chip stocks falling to more than two-week lows. The Dow Jones Industrial Average was up 0.67% as focus turned to the Federal Reserve's policy meeting. The top three S&P 500 percentage gainers were International Paper Co, up 10%.
Reuters · 03/19 17:48
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
BUZZ-U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
Tech-laden Nasdaq jumped more than 1% to a one-week high on Monday. Dow slipped to a fresh two-week low as Boeing shares tanked following the grounding of some jets. Top three S&P 500 percentage gainers: Baxter International, American Airlines Group.
Reuters · 01/08 19:09
BUZZ-U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. Blue-chip index Dow slipped to a fresh two-week low on Monday. Boeing shares fell following the grounding of some its jets. The rebound in megacaps and chip stocks supported the other U.s. Stock indexes. The Dow Jones Industrial Average was down 0.13% at 37,416.29.
Reuters · 01/08 15:57
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Dow e-minis poised for a lower open on Monday. Boeing shares tumble following grounding of some of its jets. Other major U.S. Indexes eyed a subdued open. Top three NYSE percentage gainers: Surf Air Mobility, Unifi. The top two Nasdaq percentage losers: Solo Brands and Alibaba.
Reuters · 01/08 14:30
BUZZ-Vincerx Pharma climbs on positive data from early-stage cancer therapy trial
Shares of drug developer Vincerx Pharma soars 52.5% to $1.8 premarket. Co announced positive results from its early-stage study testing its experimental combination cancer therapy. The combination therapy helped in shrinking the tumor by at least 50% in four patents.
Reuters · 01/08 12:56
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Harpoon Therapeutics, Heron Therapeutics
U.S. Stock index futures slip on Monday. Boeing tumbles after some of its jets are grounded following an incident. DoorDash, Harpoon Therapeutics, Heron Therapeutic are among the top stocks on the day. Dow e-minis down 0.41% while Nasdaq 100 up 0.07%.
Reuters · 01/08 12:24
BUZZ-U.S. STOCKS ON THE MOVE-AMTD Digital, BioXcel, Hasbro
Reuters · 08/22/2023 17:57
More
Webull provides a variety of real-time VINCU stock news. You can receive the latest news about Vincerx Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About VINCU
Vincerx Pharma, Inc., formerly Vincera Pharma, Inc., is a clinical-stage life sciences company. The Company focuses on the development and oncology knowledge to advance new therapies for the treatment of cancer. The Company’s small molecule drug program includes VIP152, a clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. Its antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.